WHAT IS CLAIMED IS:

| 1 | 1. A pharmacological composition comprising: | | | | | | |
|------------|--|--|--|--|--|--|--|
| 2 | (A) at least one biologically-active agent; and | | | | | | |
| 3 | (B) at least one carrier compound having the formula | | | | | | |
| 4 | 2-HO-Ar-CONR ⁸ -R ⁷ -COOH | | | | | | |
| _5 | wherein Ar is a substituted or unsubstituted phenyl or naphthyl; | | | | | | |
| 6 | R^7 is selected from the group consisting of C_4 to C_{20} alkyl, C_4 to C_4 | | | | | | |
| L 6 | alkenyl, phenyl, naphthyl, (C_1 to C_{10} alkyl) phenyl, (C_1 to C_{10} alkenyl) phenyl, (C_1 to C_{10} | | | | | | |
| 8 | alkyl) naphthyl, (C_1 to C_{10} alkenyl) naphthyl, phenyl (C_1 to C_{10} alkyl), phenyl (C_1 to C_{10} | | | | | | |
| 9 | alkenyl), naphthyl (C_1 to C_{10} alkyl), and naphthyl (C_1 to C_{10} alkenyl); | | | | | | |
| 9 10 | R^8 is selected from the group consisting of hydrogen, C_1 to C_4 alkyl, C_1 | | | | | | |
| 11 | to C_4 alkenyl C_1 to C_4 alkenyl, hydroxy, and C_1 to C_4 alkoxy; | | | | | | |
| 12 | R^8 is optionally substituted with C_1 to C_4 alkyl, C_1 to C_4 alkenyl, C_1 to C_4 | | | | | | |
| 12 13 | alkoxy, -OH, -SH and -CO₂R9 or any combination thereof; | | | | | | |
| 14 | R^9 is hydrogen, C_1 to C_4 alkyl or C_1 to C_4 alkenyl; | | | | | | |
| 15 | R ⁷ is optionally interrupted by oxygen, nitrogen, sulfur or any combination | | | | | | |
| 16 | thereof; | | | | | | |
| 17 | with the proviso that the compounds are not substituted with an amino | | | | | | |
| 18 | group in the position alpha to the acid group; | | | | | | |
| 19 | or salts thereof. | | | | | | |
| | į | | | | | | |
| 1 | 2. The composition according to claim 1, wherein said biologically-active | | | | | | |
| 2 | agent comprises at least one peptide, mucopolysaccharide, carbohydrate, or lipid. | | | | | | |
| 1 | 3. The composition according to claim 2, wherein said biologically active | | | | | | |
| 2 | agent is selected from the group consisting of human growth hormone, bovine growth | | | | | | |
| 3 | hormone, growth hormone-releasing hormone, an interferon, interleukin-II, insulin, | | | | | | |
| _ | | | | | | | |

- 4 heparin, calcitonin, erythropoietin, atrial ηaturetic factor, an antigen, a monoclonal
- 5 antibody, somatostatin, adrenocorticotropin, gonadotropin releasing hormone,
- 6 oxytocin, vasopressin, cromolyn sodium, vancomycin, parathyroid hormone,
- 7 desferrioxamine (DFO), or any combination thereof.
- 1 4. The composition according to claim 2, wherein said biologically-active
- 2 agent comprises an interferon, interleukin-II, insulin, heparin, calcitonin, oxytosin,
- 3 vasopressin, vancomycin, DFSO and combinations thereof.
 - 5. The composition according to claim 4, wherein said biologically-active agent comprises calcitonin.
 - 6. The composition according to claim 1, wherein R^6 is selected from the group consisting of C_4 to C_{20} alkyl and C_4 to C_{20} alkenyl.
 - 7. The composition according to claim 1, wherein R^6 is selected from the group consisting of C_5 to C_{20} alkyl and C_5 to C_{20} alkenyl.
 - 8. The composition according to claim 1 wherein the carrier has the formula

3 or salts thereof.

U

H

1

2

1 9. The composition according to claim 1 wherein said carrier is a compound 2 selected from the group consisting of

6

XXII

XXXVII

CVI

- 17 or salts thereof.
 - 1 10. The composition according to claim 1 wherein the carrier is a compound
 - 2 selected from the group consisting of

| 3 | | но | | T T m | | × | Α |
|----------|-------------------|---------------------|--------|----------|------|----------------|----------------------|
| 4 | | Compound | n | m | X | | |
| 5 | | LII | 1 | 0 | 2-0 | ЭН | |
| 6 | | LIII | 3 | 0 | 2,6 | 6-dihydroxy | |
| 7 | | LIV | 2 | 0 | 2-0 | ЭН | |
| 8 | | LVI | 2 | 0 | 2,6 | 6-dihydroxy | |
| | or salts thereof. | | | | | | |
| - | 11. The | e composition acc | ording | g to cla | im 1 | wherein the ca | arrier is a compound |
| | selected from th | ne group consisting | ng of | | × | | G |
| 4 | | Compo | und | n | m | X | . - |
| 5 | | cxı | | 6 | 0 | 2-0H | |

1 12. The composition according to claim 1, wherein said carrier has the 2 formula

2-OH

6

or salts thereof.

XIX

4 or salts thereof.

3

5

6

7

8

9

10

1 13. The composition according to claim 1, wherein said The composition

2 according to claim 1 wherein the carrier has the formula

or salts thereof.

14. A dosage unit form comprising

(A) a pharmacological composition according to claim 1; and

(B) (a) an excipient,

- (b) a diluent,
- (c) a disintegrant,
- (d) a lubricant
- (e) a plasticizer
- (f) a colorant,
- (g) a dosing vehicle, or
- (h) any combination thereof.
- 1 15. A dosage unit form according to claim 14, comprising a tablet, a capsule, 2 or a liquid.

- 1 16. A dosage unit form according to claim 15, wherein said dosing vehicle 2 is selected from the group consisting of water, 1,2-propane diol, ethanol or any 3 combination thereof.
- 1 17. A method for administering a biologically-active agent to a mammal in 2 need of said agent, said method comprising administering orally to said mammal a 3 composition as defined in claim 1.
 - 18. A method for preparing a pharmacological composition, said method comprising mixing:
 - (A) at least one biologically-active agent;
 - (B) at least one carrier compound according to claim 1; and
 - (C) optionally a dosing vehicle.
 - 19. A method for administering a biologically-active agent to a animal in need of said agent, said method comprising administering orally to said mammal a composition as defined in claim 1.